Dual Anti-BCMA/Anti-GPRC5D TCR Gamma Delta T-Cell Therapy (Eureka Therapeutics)

N/A

Report date: 2025/01/26 17:28:04

Base Information

Drug NameDual Anti-BCMA/Anti-GPRC5D TCR Gamma Delta T-Cell Therapy (Eureka Therapeutics)
Drug Alias Nameanti-BCMA/GPRC5D TCR T-cell therapy (Eureka Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulatorsG-protein coupled receptor family C group 5member D modulators
TargetsG-protein coupled receptor family C group 5member DTumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEureka Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEureka Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A